Cytek BioSciences, Inc. (CTKB) News
Filter CTKB News Items
CTKB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTKB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare ConferenceFREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the |
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 an |
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceFREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY. Cytek management is scheduled to participate in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Interested parties may access a live and archived webcast of the presentation on the “Inv |
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramBioTech Company of the Year Cytek Biosciences has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. With their patented Full Spectrum Profiling™ (FSP™) technology, Cytek is making the power, flexibility and breadth of flow cytometry more accessible, opening the door for a wider range of discoveries and equipping scientists with the tools and knowledge they need to drive a new era of discovery and innovation. FREMONT, Calif., Nov. 19, 2024 |
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterWorld’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific DiscoveriesFREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug d |
Cytek Biosciences Third Quarter 2024 Earnings: Beats ExpectationsCytek Biosciences ( NASDAQ:CTKB ) Third Quarter 2024 Results Key Financial Results Revenue: US$51.5m (up 7.3% from 3Q... |
Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...Cytek Biosciences Inc (CTKB) reports a 7% revenue growth and a positive net income, while navigating softer US market conditions and maintaining strong global demand. |
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat EstimatesCytek Biosciences (CTKB) delivered earnings and revenue surprises of 150% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Cytek Biosciences Reports Third Quarter 2024 Financial ResultsFREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 |
November 2024's Top US Penny Stocks With Growth PotentialAs investors digest the latest big-tech earnings and a crucial jobs report, stock futures are pointing to a higher open for major indexes, suggesting cautious optimism in the market. Penny stocks, often representing smaller or newer companies, remain an intriguing option for those looking beyond established giants. Despite their vintage label, these stocks can offer surprising value when backed by solid financials and present unique opportunities for growth-oriented investors. |